Imaging Biometrics

Imaging Biometrics is a healthcare technology company specializing in advanced visualization software and quantitative imaging solutions, primarily for neuro-oncology. The company develops and commercializes analytical software plug-ins that provide clinicians with automated, standardized, and validated physiological maps from standard MRI and CT scans. Their core technology focuses on perfusion imaging to differentiate between tumor progression and treatment-induced effects like pseudo-progression. As a subsidiary of IQ-AI Limited, Imaging Biometrics provides essential tools for clinical decision-making and pharmaceutical clinical trials. Their product portfolio includes FDA-cleared platforms such as IB Neuro, IB Diffusion, and IB DCE, which are integrated into major medical imaging workflows. Additionally, the company supports the development of Gallium Maltolate, an oral therapeutic agent being investigated for the treatment of glioblastoma multiforme.